Hazot Yohan 4

4 · Foamix Pharmaceuticals Ltd. · Filed Jan 24, 2018

Form 4

Period: 2018-01-01

VP Pharmaceutical Development

Transactions

Exercise/Conversion
Ordinary Shares
2018-01-15+562→ 27,300 total
Exercise/Conversion
Ordinary Shares
2018-01-01+4,575→ 27,300 total
Exercise/Conversion
Restricted Share Units
2018-01-01−4,575→ 0 total
Exercise: $0.00→ Ordinary Shares (4,575 underlying)
Exercise/Conversion
Restricted Share Units
2018-01-15−562→ 0 total
Exercise: $0.00→ Ordinary Shares (562 underlying)

Footnotes (5)

[F1]This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
[F2]The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,184 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 4,575 ordinary shares underlying restricted share units that vested on January 1, 2018, (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 15,979 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security.
[F3]The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021.
[F4]The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019.
[F5]This class of restricted share units is included in Column 5 of Table I above.

Documents

1 file